Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia

Area of Science:

• Cardiovascular medicine
• Molecular biology
• Pharmacology

Background:

• Lowering low-density lipoprotein cholesterol (LDL-C) is crucial for reducing cardiovascular disease (CVD) risk.
• Achieving increasingly stringent LDL-C goals is challenging for many individuals, especially those at high risk.
• New therapeutic strategies are needed to effectively manage dyslipidemia and prevent CVD morbidity and mortality.

Purpose of the Study:

• To investigate the potential of antisense oligonucleotides (ASOs) targeting hepatic apolipoprotein B (apoB) production as a novel therapeutic approach for lowering LDL-C.
• To evaluate the efficacy and safety of apoB ASOs in reducing LDL-C concentrations in animal models and humans.
• To explore the mechanisms underlying the effects of apoB ASOs on lipid metabolism, particularly hepatic triglyceride levels.

Main Methods:

• Development and application of novel antisense oligonucleotide sequences designed to inhibit the synthesis of apolipoprotein B (apoB).
• Administration of apoB ASOs in relevant animal models and subsequent clinical trials in human subjects.
• Monitoring of lipid profiles, including LDL-C and very low-density lipoprotein (VLDL) levels, and assessment of hepatic triglyceride content.

Main Results:

• Newly developed apoB antisense approaches demonstrated proof of concept by achieving significant reductions in LDL-C concentrations in both animal models and human studies.
• Surprisingly, apoB ASO-mediated reduction in VLDL secretion did not result in marked hepatic steatosis, unlike previous observations with microsomal triglyceride transfer protein inhibitors.
• Ongoing investigations aim to elucidate the mechanisms responsible for the differential effects of apoB inhibition versus microsomal triglyceride transfer protein inhibition on hepatic triglyceride accumulation.

Conclusions:

• Antisense oligonucleotides targeting apoB represent a viable and potentially advantageous therapeutic strategy for lowering LDL-C and managing dyslipidemia.
• This approach offers a novel way to reduce cardiovascular disease risk, particularly in populations struggling to meet lipid-lowering goals.
• The distinct impact on hepatic triglycerides compared to other VLDL secretion inhibitors warrants further mechanistic research.